Senseonics (NYSE:SENS) Now Covered by Analysts at StockNews.com

Investment analysts at StockNews.com assumed coverage on shares of Senseonics (NYSE:SENS) in a research report issued to clients and investors on Wednesday. The firm set a “sell” rating on the stock.

Separately, HC Wainwright reaffirmed a “buy” rating and issued a $2.00 price objective on shares of Senseonics in a research note on Friday, November 15th.

Senseonics Trading Up 8.9 %

Shares of SENS stock opened at $0.44 on Wednesday. The company has a quick ratio of 2.38, a current ratio of 2.47 and a debt-to-equity ratio of 59.17. The stock has a 50-day simple moving average of $0.34 and a 200 day simple moving average of $0.38. Senseonics has a fifty-two week low of $0.25 and a fifty-two week high of $0.75. The stock has a market capitalization of $263.13 million, a P/E ratio of -3.40 and a beta of 0.77.

Insider Transactions at Senseonics

In related news, CEO Timothy T. Goodnow bought 315,000 shares of Senseonics stock in a transaction dated Tuesday, December 10th. The stock was acquired at an average cost of $0.31 per share, with a total value of $97,650.00. Following the completion of the acquisition, the chief executive officer now directly owns 11,310,355 shares in the company, valued at approximately $3,506,210.05. This trade represents a 2.86 % increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, CFO Frederick T. Sullivan purchased 124,933 shares of the company’s stock in a transaction that occurred on Thursday, December 12th. The stock was bought at an average cost of $0.38 per share, for a total transaction of $47,474.54. Following the purchase, the chief financial officer now directly owns 2,478,844 shares in the company, valued at $941,960.72. This represents a 5.31 % increase in their position. The disclosure for this purchase can be found here. Corporate insiders own 3.60% of the company’s stock.

Institutional Investors Weigh In On Senseonics

A number of large investors have recently made changes to their positions in SENS. Symmetry Partners LLC acquired a new position in Senseonics in the 3rd quarter worth approximately $164,000. GSA Capital Partners LLP purchased a new stake in shares of Senseonics in the third quarter valued at $117,000. Geode Capital Management LLC lifted its holdings in shares of Senseonics by 3.2% in the third quarter. Geode Capital Management LLC now owns 5,838,396 shares of the company’s stock valued at $2,042,000 after purchasing an additional 179,103 shares in the last quarter. FMR LLC boosted its position in shares of Senseonics by 48,267.2% in the third quarter. FMR LLC now owns 168,318 shares of the company’s stock worth $59,000 after buying an additional 167,970 shares during the period. Finally, Cubist Systematic Strategies LLC grew its holdings in shares of Senseonics by 25.9% during the second quarter. Cubist Systematic Strategies LLC now owns 415,404 shares of the company’s stock valued at $166,000 after buying an additional 85,501 shares in the last quarter. Institutional investors and hedge funds own 12.36% of the company’s stock.

About Senseonics

Senseonics Holdings, Inc, a medical technology company, focuses on development and manufacturing of continuous glucose monitoring (CGM) systems for people with diabetes in the United States and internationally. The company's products include Eversense, Eversense XL, and Eversense E3 that are implantable CGM systems to measure glucose levels in people with diabetes through an under-the-skin sensor, a removable and rechargeable smart transmitter, and a convenient app for real-time diabetes monitoring and management.